The transthyretin level, a simple and economic indicator for the prognostic measure of MDS, could provide a useful supplement to IPSS-R and IPSS-M, especially for MDS patients without karyotype or mutation detections. This evidence concerns the gene TTR and myelodysplastic syndrome.